Kaleido’s Microbiome Metabolic Therapies (MMTs) drive functional outputs of the microbiome organ to treat disease and improve overall health. The company is advancing a pipeline of MMTs in multiple therapeutic areas.
The microbiome produces metabolites that are essential for human health. In many ways the microbiome operates as another human organ, metabolizing nutrients that are otherwise unavailable to humans and interacting with many parts of the body through biochemical signals. Kaleido’s Microbiome Metabolic Therapies (MMTs) drive functional outputs depending on the disease or condition. MMTs can increase the production of a metabolite, decrease the production of a metabolite, or generate changes in the microbiome community.
Kaleido’s discovery and development model enables product candidates to advance rapidly to the clinic, dramatically reducing time and cost and increasing probability of success. Our platform performs automated, high-throughput screening of proprietary, novel chemistries against human ex vivo microbiomes. Our model results in early and continuous integration of human data and higher translatability between ex vivo and in vivo studies. Additionally, the nature of our compounds allows us to advance more quickly into clinical studies in human subjects.
The human microbiome is community of trillions of microbes that live in and on us. In the past decade, there has been an exponential increase in data revealing the microbiome’s role in multiple areas of health and disease, including autoimmunity, oncology, neurobiology and metabolism. It is akin to the discovery of a new organ, with broad impacts on our ability to prevent and treat disease.
Learn why the human microbiome is one of the most exciting fields of medicine, with far reaching implications for disease and health.